Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The Taiwan location entry was updated from Taoyuan to Taoyuan City (Taiwan, 333). The postal code remains 333.
    Difference
    0.0%
    Check dated 2026-05-05T22:11:14.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The release notes now show Revision: v3.5.3, replacing the prior v3.5.2. This indicates a newer version of the page, with no changes to the study details presented.
    Difference
    0.0%
    Check dated 2026-04-28T18:31:47.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Updated the ClinicalTrials.gov page revision from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-21T16:17:11.000Z thumbnail image
  4. Check
    47 days ago
    Change Detected
    Summary
    The site revision was updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-23T22:36:37.000Z thumbnail image
  5. Check
    60 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added, replacing Revision: v3.4.2. This appears to be a minor UI/versioning update and does not affect the study information.
    Difference
    0.0%
    Check dated 2026-03-10T00:01:15.000Z thumbnail image
  6. Check
    82 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was applied, replacing the previous v3.4.1. This update seems to be a metadata/version change with no visible impact on study details or page content.
    Difference
    0.0%
    Check dated 2026-02-16T15:20:28.000Z thumbnail image

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.